about
Progress and problems in understanding and managing primary Epstein-Barr virus infectionsMonoclonal antibody therapy and renal transplantation: focus on adverse effectsEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderPosttransplant lymphoproliferative disease after pediatric solid organ transplantationTherapeutic options in post-transplant lymphoproliferative disorders.Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lyMulticenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.Progress in central nervous system lymphomas.Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004.Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).Post-transplant lymphoproliferative disorder: case report and review of susceptibility to EBV in the Scottish adult renal transplant pool.Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationLow-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.Posttransplant lymphoproliferative disease after lung transplantation.Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.New approaches in primary central nervous system lymphoma.How I treat CNS lymphomas.Comparative pathobiology of macaque lymphocryptoviruses.Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders.Management of the liver transplant patient.Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.Epstein-barr virus-negative post-transplant lymphoproliferative diseases: three distinct cases from a single centerImmunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.Post-transplant lymphoproliferative disorders following solid-organ transplantation.Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.Lymphoproliferative disorders in immunocompromised individuals and therapeutic antibodies for treatment.Opportunistic viral infections in intestinal transplantation.Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.Managing the challenge of PTLD in liver and bowel transplant recipients.
P2860
Q24597706-F2BC8DD3-81F9-4BA1-87E6-A9212FF2DA79Q26826880-B6FE7B86-6328-44A6-9649-5806B94E9C81Q26859114-8A7ED8AA-A366-43C6-927D-79096C6C9361Q26866013-6B14C708-A92E-469F-86B3-491CA7322FADQ30455714-198BA3FA-7C24-48AD-BFCE-5528420824F9Q30991629-8C0507D5-18B8-40E3-989C-05460B7FA2F8Q33710720-0B45D676-6656-46B6-88C2-12E5F4BFA2DAQ33934406-3C800882-5188-4F07-826A-090307A66275Q34056575-3ED963E0-4DD7-4231-8BAC-FFACB75DCA16Q34815054-20946548-881F-4FA8-BA51-DE5EC430FE6FQ35574186-2782DE7A-0546-493B-8954-10C052D27C0FQ35849338-06851339-46F6-484C-A860-F1E3F47D6AF8Q36356785-6C2C3BCB-5E5E-4A41-A9C7-85A43E0803F1Q36425674-7ABB8434-2181-4377-A80C-74B2006F3DD4Q36701511-2969D159-2722-4766-9BFF-FC78E0DB1E7FQ36732580-FFFB3054-F75E-4C6A-9E94-7188784EADCCQ36937549-8F233178-6012-4DAF-9E02-81DC0A5FE5CEQ37088471-F2B8F27D-4A4A-498E-9554-F6F56EC10209Q37215118-F011038B-31C6-476D-9B08-A1C948FB4E91Q37243867-AE17D986-D899-469F-A603-CDB0FBFB5EB6Q37355856-6442CC1D-97F1-4628-A009-BC02D4A2AD0FQ37423540-B35C30DE-ABDA-466A-AFB2-8202C44B135EQ37426542-62558E42-203F-4A08-A8C5-814F1D5CB3A7Q37579288-2D87626A-7451-4BA4-99FE-527AB468D766Q37636100-5D39F98F-3CE8-4F77-B4A5-5A489FCA30D0Q37662629-7CE0AE9B-0F70-4C9B-B590-531E64E2EBF8Q37718389-7639BCF7-792B-4F6C-98F6-C53E8E6387BCQ37793222-B68B177D-4A35-4ECF-9F2F-3944E36A46F9Q37801865-BDC97645-B271-48E6-A8E7-3097C10EE2BDQ37807871-387A10FB-CEF8-4F24-9649-D55A6C3F845CQ37810068-04FEC789-F29E-4B25-94E1-1DAAA0996B57Q37824825-BC1E346C-AA44-4BD0-BE5B-AEACDCD9263CQ37845384-96464EBA-0F9A-471A-BAD0-D5DAE9B12DBCQ37975458-C74AD5B6-EA6F-46EE-817F-A9B6EC72A77EQ38032320-9A71BE7C-8868-43BD-8D3D-75775288C1C4Q38096060-0B10D396-FBC9-400A-AE3E-BB4A4747FA03Q38097119-6C4468E8-369A-4C65-B0FF-987B8629F429Q38112050-6A34ABA4-73B5-456E-8E4D-3EF7C8848464Q38223160-7B3B5225-645E-4AD1-B90E-2EF8923C892DQ38265869-7BFA3D65-9044-4FB5-BE3D-9B869AAFA29A
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Treatment of PTLD with rituximab or chemotherapy.
@en
Treatment of PTLD with rituximab or chemotherapy.
@nl
type
label
Treatment of PTLD with rituximab or chemotherapy.
@en
Treatment of PTLD with rituximab or chemotherapy.
@nl
prefLabel
Treatment of PTLD with rituximab or chemotherapy.
@en
Treatment of PTLD with rituximab or chemotherapy.
@nl
P2093
P2860
P1476
Treatment of PTLD with rituximab or chemotherapy.
@en
P2093
Andreadis C
Brozena SC
Elstrom RL
Olthoff KM
Schuster SJ
Stadtmauer EA
P2860
P304
P356
10.1111/J.1600-6143.2005.01211.X
P407
P577
2006-03-01T00:00:00Z